
Artivion, Inc.
- Jurisdiction
United States - LEI
549300YTKV8DMSMG6K81 - ISIN
US2289031005 (CRY )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
6
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
6
/ 7
Profile
Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. Read full profile
Fundamentals
- Net revenue
€332.72M - Gross margin
63.9% - EBIT
€13.40M - EBIT margin
4.0% - Net income
-€18.25M - Net margin
-5.5%
Statement period: - (published )
Estimates
Fiscal Year | Net revenue | Net income |
---|---|---|
|
| |
N/A |
| |
|
|
Stock price
Dividends
- Last dividend amount
-
$0.03 - Ex date
-
- Payment date
-
Analyst ratings
No analyst ratings available
Insider Transactions
Name | Title | Transaction Date | Shares | Price | Value |
---|---|---|---|---|---|
Stanton Marshall S. | SVP, Clinical & MD Affair |
|
|
|
|
Holloway Jean F | SVP, General Counsel |
|
|
|
|
Mackin James P | President & CEO |
|
|
|
|
Davis John E | Chief Commercial Officer |
|
|
|
|
Holloway Jean F | SVP, General Counsel |
|
|
|
|
Earnings Calls
Earnings Calls
Latest earnings call: August 8, 2025 (Q2 2025)